{
  "metadata": {
    "created": "2025-07-27T19:46:37.524657",
    "detection_dpi": 200,
    "total_pages": 8,
    "pipeline_version": "3.0-fixed-coords"
  },
  "pages": {
    "1": {
      "width": 595.276,
      "height": 790.866,
      "element_ids": [
        "elem_001_0001",
        "elem_001_0002",
        "elem_001_0003",
        "elem_001_0004",
        "elem_001_0005",
        "elem_001_0006",
        "elem_001_0007",
        "elem_001_0008",
        "elem_001_0009",
        "elem_001_0010",
        "elem_001_0011",
        "elem_001_0012",
        "elem_001_0013",
        "elem_001_0014",
        "elem_001_0015",
        "elem_001_0016"
      ]
    },
    "2": {
      "width": 595.276,
      "height": 790.866,
      "element_ids": [
        "elem_002_0017",
        "elem_002_0018",
        "elem_002_0019",
        "elem_002_0020",
        "elem_002_0021",
        "elem_002_0022",
        "elem_002_0023",
        "elem_002_0024",
        "elem_002_0025",
        "elem_002_0026"
      ]
    },
    "3": {
      "width": 595.276,
      "height": 790.866,
      "element_ids": [
        "elem_003_0027",
        "elem_003_0028",
        "elem_003_0029",
        "elem_003_0030",
        "elem_003_0031",
        "elem_003_0032",
        "elem_003_0033",
        "elem_003_0034",
        "elem_003_0035"
      ]
    },
    "4": {
      "width": 595.276,
      "height": 790.866,
      "element_ids": [
        "elem_004_0036",
        "elem_004_0037",
        "elem_004_0038",
        "elem_004_0039",
        "elem_004_0040"
      ]
    },
    "5": {
      "width": 595.276,
      "height": 790.866,
      "element_ids": [
        "elem_005_0041",
        "elem_005_0042",
        "elem_005_0043",
        "elem_005_0044",
        "elem_005_0045",
        "elem_005_0046",
        "elem_005_0047",
        "elem_005_0048",
        "elem_005_0049",
        "elem_005_0050",
        "elem_005_0051"
      ]
    },
    "6": {
      "width": 595.276,
      "height": 790.866,
      "element_ids": [
        "elem_006_0052",
        "elem_006_0053",
        "elem_006_0054",
        "elem_006_0055",
        "elem_006_0056",
        "elem_006_0057",
        "elem_006_0058",
        "elem_006_0059",
        "elem_006_0060",
        "elem_006_0061",
        "elem_006_0062",
        "elem_006_0063",
        "elem_006_0064",
        "elem_006_0065",
        "elem_006_0066",
        "elem_006_0067",
        "elem_006_0068"
      ]
    },
    "7": {
      "width": 595.276,
      "height": 790.866,
      "element_ids": [
        "elem_007_0069",
        "elem_007_0070",
        "elem_007_0071",
        "elem_007_0072",
        "elem_007_0073"
      ]
    },
    "8": {
      "width": 595.276,
      "height": 790.866,
      "element_ids": [
        "elem_008_0074",
        "elem_008_0075",
        "elem_008_0076",
        "elem_008_0077",
        "elem_008_0078",
        "elem_008_0079",
        "elem_008_0080",
        "elem_008_0081",
        "elem_008_0082",
        "elem_008_0083",
        "elem_008_0084",
        "elem_008_0085",
        "elem_008_0086",
        "elem_008_0087",
        "elem_008_0088",
        "elem_008_0089",
        "elem_008_0090"
      ]
    }
  },
  "elements": [
    {
      "element_id": "elem_001_0001",
      "page_num": 1,
      "element_type": "title",
      "bbox": [
        34.747816772460936,
        387.051240234375,
        98.867109375,
        398.17248046875
      ],
      "confidence": 0.9984456896781921,
      "reading_order": 1,
      "content": "INTRODUCTION"
    },
    {
      "element_id": "elem_001_0002",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        34.28806915283203,
        608.8109326171875,
        287.18578125,
        701.300390625
      ],
      "confidence": 0.9943521022796631,
      "reading_order": 2,
      "content": "Haemagglutinin(HA)istheprimaryantigenintheinductionof\na protective immune response against the influenza virus, and\nthus a key vaccine target. Expressed as trimeric glycoproteins on\ntheviralsurface,HAbindstosialicacidontargetcellstofacilitate\nhostcellentryandmediatesthefusionoftheviralenvelopetothe\nlateendosomalmembrane.NeutralisingantibodiesthatblockHA\neffectively prevent viral entry into target cells and have been\nshowntoprotectthehostfrominfection10,11.Anotherviralsurface\nprotein, neuraminidase (NA), cleaves sialic acid and releases"
    },
    {
      "element_id": "elem_001_0003",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        35.3551821899414,
        507.0873779296875,
        282.6301904296875,
        608.325380859375
      ],
      "confidence": 0.992618978023529,
      "reading_order": 3,
      "content": "InfluenzaAsubtypesH1N1andH3N2,andinfluenzaBlineage\nB/Yamagata and B/Victoria circulate routinely in humans and ar\nincludedinseasonalinfluenzavaccines8.InfluenzaAsubtypesca\nalsogiverisetohighlypathogenicvirusesthroughcross-overfro\nanimal reservoirs to humans9. In the past century, four nove\ninfluenzaAvirusstrainshaveemergedinthisway,eachleadingt\na global pandemic (H1N1 in 1918; H2N2 in 1957; H3N2 in 1968\nandH1N1in2009).Vaccinesagainstsuchstrainsarepreparedan\nstockpiled as government initiatives for emergency use i"
    },
    {
      "element_id": "elem_001_0004",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        35.05644470214843,
        397.727841796875,
        284.17403320312496,
        509.0659716796875
      ],
      "confidence": 0.9939171671867371,
      "reading_order": 4,
      "content": "Seasonal influenza is responsible for 290,000\u2013650,000 deaths per\nyear due to respiratory diseases alone and 3\u20135 million cases of\nsevereillnessworldwide1\u20133.IntheUSA,influenzawasthoughtto\naccount for 52.7 hospitalisations per 100,000 people during the\n2019\u20132020 season. These numbers are significantly higher in\nyoungchildrenandadultsaged65andolder1,2,4.Extra-pulmonary\ncomplications of influenza infection constitute a further under-\nrecogniseddiseaseburden4,5.Overall,suchahighdiseaseburden\ncarries substantial social and economic cost6,7. Prevention of\nseasonal influenza epidemics, as well as preparedness for future\npandemics,is thusaglobal priority."
    },
    {
      "element_id": "elem_001_0005",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        33.21237854003906,
        151.59834228515624,
        273.558427734375,
        162.66554077148436
      ],
      "confidence": 0.9735447764396667,
      "reading_order": 5,
      "content": "ArunB.Arunachalam ,PennyPost and Deborah Rudin"
    },
    {
      "element_id": "elem_001_0006",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        51.047336425781246,
        339.83958251953123,
        309.52997314453125,
        349.8869311523437
      ],
      "confidence": 0.7284221053123474,
      "reading_order": 6,
      "content": "(2021) 6:144 ; https://doi.org/10.1038/s41541-021-00403-"
    },
    {
      "element_id": "elem_001_0007",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        36.63035980224609,
        717.5759326171875,
        546.9064453125,
        736.25291015625
      ],
      "confidence": 0.985614001750946,
      "reading_order": 7,
      "content": "AnalyticalSciences,R&DSano Pasteur,1DiscoveryDrive,Swiftwater,PA18370,USA. RegulatoryAffairs,ProteinSciences,aSano Company,1000ResearchParkway,Meride\nT06450,USA.3GlobalMedicalAffairs,SanofiPasteur,1DiscoveryDrive,Swiftwater,PA18370,USA. \u2709 email:Arun.Arunachalam@sanofi.com"
    },
    {
      "element_id": "elem_001_0008",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        41.327347412109376,
        252.33150146484374,
        533.1979248046874,
        328.690810546875
      ],
      "confidence": 0.957181453704834,
      "reading_order": 8,
      "content": "structuralfeatures.Theabsenceofprotease-drivencleavageandadditionofsimpleN-linkedglycanshelptopreserveandexpo\ncertainconservedepitopesonHAmolecules,whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotecti\nantibodieswithrarespecificitiesobservedwithRIV4.Furthermore,thepresenceofuniformcompactHAoligomersandabsence\neggproteins,viralRNAorprocessimpurities,typicallyfoundinconventionalvaccines,areexpectedtoeliminatepotentialadver\nreactionstothesecomponentsinsusceptibleindividualswiththeuseofRIV4.Thesedistinctstructuralfeaturesandpurityofth\nrecombinantHAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltarget"
    },
    {
      "element_id": "elem_001_0009",
      "page_num": 1,
      "element_type": "list",
      "bbox": [
        43.425208740234375,
        182.0454345703125,
        545.8387060546875,
        340.00048828125
      ],
      "confidence": 0.5506378412246704,
      "reading_order": 9,
      "content": "Thein uenzavaccine eldhasbeenconstantlyevolvingtoimprovethespeed,scalability,and exibilityofmanufacturing,andto\nimprovethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration\nvaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector\nsystemtoexpressrecombinanthaemagglutinin(rHA)ininsectcells,istheonlyonetohavereachedthemarketandhasbeen\nstudiedextensively.WedescribehowtheuniquestructuralfeaturesofrHAinRIV4improveprotectiveimmuneresponsescompared\ntoconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristicof\nrecombinantproteins,uniquepost-translationalprocessingoftherHAininsectcellsinstillsfavourabletertiaryandquaternary\nstructuralfeatures.Theabsenceofprotease-drivencleavageandadditionofsimpleN-linkedglycanshelptopreserveandexpose\ncertainconservedepitopesonHAmolecules,whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotective\nantibodieswithrarespecificitiesobservedwithRIV4.Furthermore,thepresenceofuniformcompactHAoligomersandabsenceof\neggproteins,viralRNAorprocessimpurities,typicallyfoundinconventionalvaccines,areexpectedtoeliminatepotentialadverse\nreactionstothesecomponentsinsusceptibleindividualswiththeuseofRIV4.Thesedistinctstructuralfeaturesandpurityofthe\nrecombinantHAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltargets,\nsuchasforCOVID-19."
    },
    {
      "element_id": "elem_001_0010",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        46.30133056640625,
        178.87327514648436,
        526.4232714843749,
        339.35302001953124
      ],
      "confidence": 0.9032245874404907,
      "reading_order": 10,
      "content": "Theinfluenzavaccinefieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,andflexibilityofmanufacturing,an\nimprovethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgenerat\nvaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionve\nsystemtoexpressrecombinanthaemagglutinin(rHA)ininsectcells,istheonlyonetohavereachedthemarketandhasbee\nstudiedextensively.WedescribehowtheuniquestructuralfeaturesofrHAinRIV4improveprotectiveimmuneresponsescompa\ntoconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristic\nrecombinantproteins,uniquepost-translationalprocessingoftherHAininsectcellsinstillsfavourabletertiaryandquaternary\nstructuralfeatures.Theabsenceofprotease-drivencleavageandadditionofsimpleN-linkedglycanshelptopreserveandexp\ncertainconservedepitopesonHAmolecules,whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotec\nantibodieswithrarespecificitiesobservedwithRIV4.Furthermore,thepresenceofuniformcompactHAoligomersandabsenc\neggproteins,viralRNAorprocessimpurities,typicallyfoundinconventionalvaccines,areexpectedtoeliminatepotentialadv\nreactionstothesecomponentsinsusceptibleindividualswiththeuseofRIV4.Thesedistinctstructuralfeaturesandpurityof\nrecombinantHAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltarg\nsuchasforCOVID-19."
    },
    {
      "element_id": "elem_001_0011",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        47.62025573730469,
        181.50901611328123,
        540.682998046875,
        241.47358154296873
      ],
      "confidence": 0.8422566056251526,
      "reading_order": 11,
      "content": "Thein uenzavaccine eldhasbeenconstantlyevolvingtoimprovethespeed,scalability,and exibilityofmanufacturing,andto\nimprovethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration\nvaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector\nsystemtoexpressrecombinanthaemagglutinin(rHA)ininsectcells,istheonlyonetohavereachedthemarketandhasbeen\nstudiedextensively.WedescribehowtheuniquestructuralfeaturesofrHAinRIV4improveprotectiveimmuneresponsescompared"
    },
    {
      "element_id": "elem_001_0012",
      "page_num": 1,
      "element_type": "title",
      "bbox": [
        23.642270507812498,
        98.54785766601562,
        536.6185400390625,
        143.76539794921874
      ],
      "confidence": 0.9803076386451721,
      "reading_order": 12,
      "content": "Unique features of a recombinant haemagglutinin in uenza\nfl\nvaccine that in uence vaccine performance"
    },
    {
      "element_id": "elem_001_0013",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        301.73644775390625,
        647.5705224609375,
        549.0770800781249,
        699.584853515625
      ],
      "confidence": 0.9940469264984131,
      "reading_order": 13,
      "content": "The annual production of influenza vaccine through conven\ntional, mostly egg-based platforms, is arduous and a race\nagainst-time21. The production process, from the selection o\ninfluenza strains to vaccine manufacture and release fo\ndistribution,takeseighttoninemonthseachyear.Agile,reliabl"
    },
    {
      "element_id": "elem_001_0014",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        302.024091796875,
        535.9396728515625,
        551.2891113281249,
        649.046162109375
      ],
      "confidence": 0.9889411330223083,
      "reading_order": 14,
      "content": "Influenza vaccines can afford significant protection against\nnfluenza illness, even when there is an antigenic mismatch\ngainst the predominant circulating virus strains16,17. Such cross-\nrotectioncanoccurthroughtheprimingoftheimmunesystem\ny vaccination or natural infection and is primarily due to\nntibodies specific to conserved regions on the HA head and\ntem18. Vaccines that can induce immunity specific to circulating\nild-typestrainsandcross-protectiontorelatedstrainswouldbe\ndeal against constantly evolving influenza viruses. As such, the\nonserved regions on the HA head and stem present attractive\nargetsfor developmentof universalinfluenzavaccines19,20."
    },
    {
      "element_id": "elem_001_0015",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        301.03916748046873,
        436.947626953125,
        550.0652343749999,
        542.3653564453125
      ],
      "confidence": 0.9664266109466553,
      "reading_order": 15,
      "content": "Thepreparationoftheannual in uenzavaccine rstly requires\nthe identification of the influenza strains and their like strains,\nmostlikelytospreadduringtheupcomingseason,forinclusionin\nthe vaccine. Identification of the target influenza strains is based\non surveillance data collected by World Health Organization\n(WHO) collaborating centres at six locations in the UK, USA\n(includingtheCentersforDiseaseControlandPrevention[CDC]),\nJapan, China and Australia as part of the WHO Global Influenza\nSurveillanceandResponseSystem(GISRS)15.Thefinaldecisionon\nresultingvaccinetargetsismadebyindividualregulatorybodies."
    },
    {
      "element_id": "elem_001_0016",
      "page_num": 1,
      "element_type": "text",
      "bbox": [
        303.16693359375,
        387.15169921874997,
        550.47779296875,
        436.31789062499996
      ],
      "confidence": 0.9860973358154297,
      "reading_order": 16,
      "content": "udding virus from the infected cells, thus serving as another\nmportant vaccine target. Although the presence of NA is not\nequired for effective vaccine performance12, its inclusion in\nnnualinfluenzavaccinationmayhelptobroadenprotectionand\nfl 13,14"
    },
    {
      "element_id": "elem_002_0017",
      "page_num": 2,
      "element_type": "text",
      "bbox": [
        45.509842529296876,
        694.815380859375,
        293.0445703125,
        735.7447705078125
      ],
      "confidence": 0.985846221446991,
      "reading_order": 1,
      "content": "Lower vaccine effectiveness estimates have been observed fo\n3N2thanforotherstrainssince2009,evenduringseasonswhe\nhe selected vaccine strain appeared to be well matched t\nirculating strains27. Differences in HA glycosylation between th"
    },
    {
      "element_id": "elem_002_0018",
      "page_num": 2,
      "element_type": "text",
      "bbox": [
        46.45809448242187,
        472.4979345703125,
        292.37675537109374,
        695.71265625
      ],
      "confidence": 0.9943491816520691,
      "reading_order": 2,
      "content": "knownriskoftraditionalsplitorsubunitvaccinesisthepotentia\nor thecandidate vaccine virus or working virus seeds to acquir\ndaptivemutationsastheygrowinembryonatedchickeneggo\nammalianhostcellsduringvaccinemanufacture.Suchadaptiv\nutations in HA peptides may reduce the effectiveness of th\nesultant vaccine24\u201326. Raymond et al.24 showed that an egg\ndapted A/California/07/2009 (H1N1) vaccine strain acquired\nutation resulting in the substitution of glutamine with arginin\nt position 226 which in turn induced antibodies specific t\neceptorbindingsitethatboundtovaccine-derivedHApreferen\niallyoverthecirculatingwild-typevirus24.Duringthe2012\u2013201\northernhemisphereinfluenzavaccinationcampaign,HAfroma\ngg-adapted A/Victoria/361/2011 (H3N2) virus used for vaccin\nanufacturing differed from the WHO-recommended prototyp\nnd several other wild-type influenza viruses in three positions\n156Q,G186V,andS219Y25.Thelowvaccineeffectiveness(41%\nbserved for H3N2 in the 2012\u20132013 season was attributed t\nhese three mutations during vaccine production25. Othe\nntigenicmutationsintroducedbyegg-adaptationofthevaccin\ntrain during vaccine manufacturing are thought to hav\nontributed to low vaccine effectiveness estimates for H3N2 i\ntherinfluenzaseasons26,27."
    },
    {
      "element_id": "elem_002_0019",
      "page_num": 2,
      "element_type": "title",
      "bbox": [
        45.65138763427734,
        443.99970703125,
        286.7105346679687,
        474.6218115234375
      ],
      "confidence": 0.9562699198722839,
      "reading_order": 3,
      "content": "OTENTIALANTIGENIC MISMATCH OFINFLUENZA VACCINE\nIRUSGROWNINEGGORCELLS DUETO ADAPTIVE\nUTATIONSINTHEHA PRIMARY STRUCTURE"
    },
    {
      "element_id": "elem_002_0020",
      "page_num": 2,
      "element_type": "text",
      "bbox": [
        43.590830383300776,
        355.07713623046874,
        295.18969482421875,
        427.521181640625
      ],
      "confidence": 0.9945554733276367,
      "reading_order": 4,
      "content": "This review focuses on the structural features of BEVS-derived\nrHAthatmakeRIV4uniquefromconventionalvaccines,andhow\nthese features help to maximise vaccine performance. Notably,\nthe benefits of this manufacturing process can be extended to\nother viral targets, such as COVID-19, where the preservation of\nconserved epitopes is critical for imparting cross-protection\nagainsta constantlyevolvingand mutating virus."
    },
    {
      "element_id": "elem_002_0021",
      "page_num": 2,
      "element_type": "text",
      "bbox": [
        43.48760559082031,
        56.75430541992187,
        292.7242529296875,
        357.5863256835937
      ],
      "confidence": 0.975526750087738,
      "reading_order": 5,
      "content": "and egg-free technologies allowing for guaranteed and faste\nmanufacture of influenza vaccines are needed to ensure timel\ndelivery for upcoming epidemic seasons and during potentia\navian flu pandemics, when egg supply may be impacted. Th\nadoption of alternative vaccine development approache\n(including mRNA, vector, and recombinant protein strategies\nin the urgent response to the COVID-19 pandemic ha\ndemonstrated the feasibility of using more efficient methods t\nproducenew,effectivevaccineswithinaccelerateddevelopmen\ntimelines.Therecombinantquadrivalentinfluenzavaccine(RIV4\nFlublok\u00ae, Supemtek\u00ae [EU, Canada], Sanofi Pasteur) was the firs\nlicensed influenza vaccine to be produced using recombinan\nviralproteinsinsteadofantigensderivedfromliveinfluenzaviru\n(as for inactivated split-virion and subunit vaccines). RIV4 is a\nunadjuvantedvaccinecontaining45\u00b5gofHA/dosefromeacho\nthe four strains. The production of RIV4 is based on a nove\nproductionplatforminwhichrecombinantHA(rHA)isexpresse\nin insect cells using a baculovirus expression vector syste\n(BEVS)22. In brief, expresSF+insect cells are infected wit\nrecombinant baculovirus carrying the relevant influenza H\ngenes, which are expressed under the control of a baculoviru\npolyhedrin promotor. rHA molecules from the infected cells ar\nextracted using detergent and purified from the clarified cel\nextract using column chromatographies followed by Q mem\nbrane filtration. Purified rHA is suspended in relevant buffe\nusing tangential flow filtration and passed through steril\nfiltration for storage and formulation22. RIV4 has undergon\nextensiveclinicalassessment23,andwasfirstapprovedbyFDAi\n2013. It is now licensed in the USA, Canada, Europe, Australia\nand various other countries."
    },
    {
      "element_id": "elem_002_0022",
      "page_num": 2,
      "element_type": "title",
      "bbox": [
        310.1854614257812,
        403.7360009765625,
        481.83956542968747,
        414.5933056640625
      ],
      "confidence": 0.9977594614028931,
      "reading_order": 6,
      "content": "RECOMBINANTHA EXPRESSIONSYSTEMS"
    },
    {
      "element_id": "elem_002_0023",
      "page_num": 2,
      "element_type": "text",
      "bbox": [
        311.72923828125,
        685.0436132812499,
        559.7225244140625,
        736.803984375
      ],
      "confidence": 0.992691695690155,
      "reading_order": 7,
      "content": "Vaccinescontainingplant-derivedrHAeitherinsolubleformor\nn virus-like particles (VLPs) have been shown to be safe and\nmmunogenic in humans34\u201337. A plant-derived recombinant\nuadrivalent VLP (QVLP) at 30\u00b5g dose per strain was found to\ne non-inferior in terms of vaccine efficacy against respiratory"
    },
    {
      "element_id": "elem_002_0024",
      "page_num": 2,
      "element_type": "text",
      "bbox": [
        311.50799560546875,
        413.94282714843746,
        559.34419921875,
        687.2477783203125
      ],
      "confidence": 0.9731311202049255,
      "reading_order": 8,
      "content": "oth prokaryotic and eukaryotic expression systems have bee\nsed for the manufacture of rHA vaccine antigens. The firs\nandidate recombinant influenza vaccines to be successfull\nanufactured using an Escherichia coli fermentation system\nnvolved expression of the globular head domain of the H\nrotein genetically fused with the Toll-like receptor 5 agonist\nalmonella typhimurium flagellin type 229. The resultant vaccine\nlicited strong and protective antibody responses in mous\nodels29.InPhase1clinicalevaluation,aprototypicquadrivalen\naccine developed using this E. coli platform elicited immun\nesponses in healthy adults with favourable tolerability30. Th\n. coli expression system has been shown to generate a hig\nields of rHA (200mg/L of purified HA protein) using a minima\numberofbioreactors31.Theauthorsprojectedthatthestrateg\nould yield up to half a billion doses of vaccine per month in\nedium-scalepharmaceuticalproductionfacility31.Thisapproac\nill likely shorten the entire vaccine manufacturing process32\nowever, E. coli-expressed rHA proteins can be subject to mis\nolding, contain impurities (e.g., host-cell proteins), and do no\nndergo glycosylation33. They therefore need extensive proces\ning to attain desired purity and to fold to their nativ\nonformation31. The resulting processed proteins are less\nmmunogenic than egg-derived antigens, with around a 10-fold\nreater quantity needed to generate protective immunity i\nnimal models31. These inherent complications have prevented\narge scale manufacturing and eventual commercialisation o\n. coli-expressed influenza vaccines."
    },
    {
      "element_id": "elem_002_0025",
      "page_num": 2,
      "element_type": "text",
      "bbox": [
        309.24052734375,
        263.9535864257812,
        559.002216796875,
        386.53048828125
      ],
      "confidence": 0.9972448348999023,
      "reading_order": 9,
      "content": "Recombinant DNA technology avoids the risk of the viru\nacquiring egg-or cell-adaptedmutations duringthemanufactur\ning process as it does not use \u2018live\u2019 influenza virus. Instead, DN\ncoding for HA is cloned from a reference virus published in th\nGlobal Initiative on Sharing All Influenza Data (GISAID) databas\nandis confirmed for fidelityat theworking virus bank level28.A\nsuch,theprimaryamino-acidsequenceoftherHAproducedusin\nbaculovirusorotherrecombinantexpressionsystemisidenticalt\nthe HA from the wild-type virus isolate selected for seasona\ninfluenzavaccineproduction.Thus,theriskofantigenicmismatc\nofRIV4,orotherrHAvaccinesindevelopment,withthewildtyp\ninfluenzastrain selected forvaccines is eliminated."
    },
    {
      "element_id": "elem_002_0026",
      "page_num": 2,
      "element_type": "text",
      "bbox": [
        310.0489233398437,
        55.667801513671876,
        559.6372265625,
        266.99150390625
      ],
      "confidence": 0.9887930750846863,
      "reading_order": 10,
      "content": "vaccine strains and circulating strains are thought to have\ncontributed to this reduced vaccine effectiveness26. During the\n2014\u20132015influenzaseason,aclade3C.2aH3N2strainpossessing\na new predicted HA glycosylation site emerged26. For the\n2016\u20132017 season,theinfluenzavaccinewasupdated toinclude\na clade 3C.2a H3N2 strain (A/Colorado/15/2014) containing\nthenewglycosylationsite26.However,thisparticularglycosylation\nsite was absent in the egg-adapted virus. Consequently, anti-\nbodies induced in humans, and in ferrets, poorly neutralised the\nglycosylated clade 3C.2a H3N2 strain26. Contrary to the egg-\nderived vaccines and as expected, rHA containing the new\nglycosylation site induced optimal levels of antibodies that\nefficiently recognised the glycosylated clade 3C.2a H3N2 virus26.\nThe chances of introducing deleterious mutations through the\nadaptation ofseedvirus duringvaccine manufacturing todayare\nlowduetothestringentqualitycontroloftheworkingseedvirus.\nIndeed,aspercurrentregulatoryrequirements,seedvirusesmust\nbe confirmed for both genetic and antigenic match with their\noriginating wild-type virus before they can be used for vaccine\nproduction.Nonetheless,thetimeittakestogenerateappropriate\nseeds could hinderthetimelyavailability ofthevaccines."
    },
    {
      "element_id": "elem_003_0027",
      "page_num": 3,
      "element_type": "text",
      "bbox": [
        35.78086944580078,
        611.6582373046875,
        283.5293994140625,
        736.9537939453124
      ],
      "confidence": 0.9972500205039978,
      "reading_order": 1,
      "content": "RIV4 is one of only two available influenza vaccines that ar\negg-free. Like other recombinant vaccines, expression of HA i\ninsect cells does not depend on the generation of reassortan\ncandidate vaccine viruses selected for robust growth in embryo\nnated eggs or mammalian cell-lines. Instead, HA geneti\nsequences from the wild-type strains selected for inclusion i\nthevaccineareinsertedintotheBEVS,fromwhichhighyieldso\nrHA are harvested and purified (Fig. 1). This process requires les\nthan half the time (2\u20133 months) required for the manufacture o\nconventionalinfluenzavaccines42,43.Thisisacriticaladvantagefo\nthetimelysupplyofinfluenzavaccineforbothseasonalepidemic\nandinpandemicsituations.VLPshavebeenproducedsuccessfull"
    },
    {
      "element_id": "elem_003_0028",
      "page_num": 3,
      "element_type": "text",
      "bbox": [
        34.95655975341797,
        480.66433593749997,
        281.91181640625,
        614.27126953125
      ],
      "confidence": 0.9955484867095947,
      "reading_order": 2,
      "content": "Several groups have explored the use of adenovirus (AdV\nprimarily as a replication-defective vector, for gene delivery an\ntransgeneexpressionofrHAinthehostcells.AdVvectorsinduc\nbothcell-mediatedandhumoralimmunityagainsttheexpresse\nprotein, providing robust protection against the targete\ndisease39\u201341.However,pre-existingoracquiredimmunityagains\nadenovirus can hamper vaccine effectiveness by neutralisin\nthe vaccine vector and clearing the vector-infected cells. Whil\nthe use of non-human adenovirus vectors could potentiall\novercome this issue, AdV vector immunity developed throug\nrepeated immunisation (for example during repeated annua\ninfluenza vaccinations) can dampen the immune respons\nagainst the vaccine antigens39,40."
    },
    {
      "element_id": "elem_003_0029",
      "page_num": 3,
      "element_type": "text",
      "bbox": [
        37.768785095214845,
        300.138662109375,
        283.33423828125,
        487.17531738281247
      ],
      "confidence": 0.9855679273605347,
      "reading_order": 3,
      "content": "llness and influenza-like illness to a quadrivalent inactivate\nnfluenza vaccine (QIV; Fluarix Quadrivalent, GlaxoSmithKline\niven at 15\u00b5g dose/strain in adults aged 18 to 64 years37\nowever,inconsistencyintheexpressionlevelsoftargetproteins\nue to nonspecific integration of transgene(s) into the hos\nenome,hasbeenamajorchallengewithplant-basedexpressio\nystems34.Theunpredictable yieldcould adversely impacttimel\naccineproduction,whichtypicallyinvolvesupdatingatleaston\nA component of the vaccine to reflect antigenic change i\nhe circulating influenza viruses each season. A unique positiv\nttribute of plant-derived rHA is that it can stimulate innat\nmmunity that predominantly facilitates Type 1 pro-inflammator\nellular immune responses, potentially as a direct effect of th\nlant-origin lipids/glycolipids in the vaccine formulation38. Thes\ntimulatory components in a plant-derived vaccine may need t\necontrolledandkeptataconstantlevel,forcommercialisation\no avoid potential severe adverse events caused by enhance\nmmuneresponses invaccinees."
    },
    {
      "element_id": "elem_003_0030",
      "page_num": 3,
      "element_type": "text",
      "bbox": [
        35.03931976318359,
        263.578974609375,
        549.0259277343749,
        291.070546875
      ],
      "confidence": 0.8668315410614014,
      "reading_order": 4,
      "content": "Fig.1 GenerationofrHAusingthebaculovirus-insectcellexpressionsystemforthemanufactureofRIV4.BVbaculovirus.Figureadapte\nfromCox,M.M.&Hashimoto,Y(2011).Afasttrackinfluenzavirusvaccineproducedininsectcells.JInvertebrPathol107Suppl,S31-41\u00a9201\nElsevierInc,withpermissionfromElsevier23."
    },
    {
      "element_id": "elem_003_0031",
      "page_num": 3,
      "element_type": "figure",
      "bbox": [
        87.02554504394531,
        53.83488098144531,
        527.1608935546875,
        250.0171435546875
      ],
      "confidence": 0.9968974590301514,
      "reading_order": 5
    },
    {
      "element_id": "elem_003_0032",
      "page_num": 3,
      "element_type": "text",
      "bbox": [
        300.95343017578125,
        643.51037109375,
        550.1648583984374,
        735.80203125
      ],
      "confidence": 0.9959327578544617,
      "reading_order": 6,
      "content": "In uenza HA is synthesised as a single precursor polypeptide\n(HA0),whichisgenerallycleavedintotwopolypeptides(HA1and\nHA2) extracellularly by trypsin-like serine proteases, furin and\nother subtilisin family endoproteases after newly synthesised\nvirions are released from infected cells50,51. HA cleavage is\nessential for the infectivity of influenza virus. Thus, expression of\nthese proteases exclusively in the respiratory tract is responsible\nfor influenza virus tropism to epithelial cells of the upper and\nlower respiratory tract. However, HA from influenza subtypes H5"
    },
    {
      "element_id": "elem_003_0033",
      "page_num": 3,
      "element_type": "title",
      "bbox": [
        301.2702978515625,
        621.8478369140624,
        553.5061523437499,
        642.6418798828125
      ],
      "confidence": 0.9597947597503662,
      "reading_order": 7,
      "content": "THETERTIARY STRUCTUREOFRECOMBINANT HA PRODUCED\nININSECTCELLSCANINFLUENCEVACCINEIMMUNOGENICITY"
    },
    {
      "element_id": "elem_003_0034",
      "page_num": 3,
      "element_type": "text",
      "bbox": [
        301.86973388671873,
        459.8144384765625,
        548.996220703125,
        603.8608447265625
      ],
      "confidence": 0.993380069732666,
      "reading_order": 8,
      "content": "Insect cell-derived rHA (RIV4) has been studied extensively b\nvarious groups in both pre-clinical models and humans. The rH\ncontainedinRIV4differs fromthatexpressedinother systemsi\nterms of specific structural features, the nature of the sourc\nmaterialandthemanufacturingprocess,whichhaveanimpacto\ncertain aspects of vaccine safety and efficacy (Fig. 2). Based o\nthese unique features, RIV4 received \u2018product exclusivity\u2019 protec\ntion from FDA, a \u2018new active substance\u2019 designation from EM\nCommittee for Medicinal Products for Human Use (CHMP)48 an\nan\u2018innovativedrug\u2019designationfromHealthCanada49.Theuseo\nthis technology, together with the molecular characterisation o\nthe product, should facilitate continued evolution of influenz\nvaccines with improved effectivenessand theirtimely availabilit"
    },
    {
      "element_id": "elem_003_0035",
      "page_num": 3,
      "element_type": "text",
      "bbox": [
        301.45941650390625,
        297.7007739257812,
        548.54947265625,
        463.5590625
      ],
      "confidence": 0.995470404624939,
      "reading_order": 9,
      "content": "by integrating HA, capsid protein (M1) and neuraminidase (NA\nexpressedininsectcells44\u201346.AlthoughpresentingproteinsinVL\nstructures enhanced their immunogenicity, it compromised th\npurity of the vaccines considerably, as VLP structures als\nintegrated both baculovirus and Sf9 cell proteins. Elimination o\nthese unwanted proteins from the vaccine required extensiv\ndisassemblyandreassemblyprocessingofpurifiedVLPs,whichi\na constraint for the commercial scale manufacturing of vaccine\nannually.Italso raises thecostand thetime ittakestobringth\nvaccines to the market. The yield and the cost of variou\nmanufacturing processes and technologies are critical element\nto ensure adequate supply of vaccine at an affordable cost\nespecially in a pandemic situation. This aspect of the vaccin\nmanufacturing has been discussed exhaustively in a repor\npublished by the Program for Appropriate Technology in Healt\n(PATH)and is notcovered here47."
    },
    {
      "element_id": "elem_004_0036",
      "page_num": 4,
      "element_type": "text",
      "bbox": [
        45.67667816162109,
        644.1880078125,
        295.99305908203127,
        735.9500390625
      ],
      "confidence": 0.9976961016654968,
      "reading_order": 1,
      "content": "The conformational differences between pre-fusion and post-\nusion states of HA and the process of exposure of the fusion\neptide have been well described54. Webster et al.57 demon-\ntrated, using monoclonal antibodies, that neutralising epitopes\nresentinthepre-fusionHA0moleculewerelostuponconversion\no the post-fusion HA1\u2013HA2 heterodimer at an acidic pH57.\nimilarly, several broadly neutralising antibodies directed against\nhe highly conserved HA stem region have been shown to block\nAmaturationandfusion58.Someoftheseantibodiesarelikelyto"
    },
    {
      "element_id": "elem_004_0037",
      "page_num": 4,
      "element_type": "text",
      "bbox": [
        47.09525207519531,
        438.47230957031246,
        293.7716015625,
        643.8263378906249
      ],
      "confidence": 0.9924742579460144,
      "reading_order": 2,
      "content": "nd H7 contains multi-basic cleavage sites that are cleaved by\nbiquitously expressed furin in the trans-Golgi network, making\nhesestrainshighlyvirulent50,52,53.TheHA1andHA2polypeptides\nemaincovalentlylinkedbyadisulfidebondtoformheterodimers\nFig. 2). These molecules, either uncleaved HA0 or cleaved\nA1\u2013HA2 heterodimers, are expressed on the viral membrane\nurface as trimers (HA \u2018rosettes\u2019). The conversion of HA0 to\nA1\u2013HA2 heterodimers leads to conformational changes that\nenderthemoleculefusion-competent,thusenablingthevirusto\nnfect a new host cell52,54. In inactivated (split and subunit)\naccines,theHAmoleculesderivedfromliveinfluenzavirusesare\nresentpredominantlyasHA1\u2013HA2heterodimers.Bycontrast,the\nHAincludedinRIV4isdesignedtoyieldpredominantlyasasingle\nA0polypeptide(Fig.2).Apreviousbiochemicalstudy(usingSDS-\nAGE under reducing conditions) clearly demonstrated the\nredominanceofHA0inrecombinantHAH7 subunitcomplexes,\nroducedusingaBEVS,withnoproteinbandsindicativeofHA1or\nA2 molecules55. Poor processing of HA0 to HA1 and HA2\nolypeptidesinSf9cellshasbeenshowntobeduetoinsufficient\n56"
    },
    {
      "element_id": "elem_004_0038",
      "page_num": 4,
      "element_type": "figure",
      "bbox": [
        65.79117004394531,
        52.3698046875,
        508.940771484375,
        357.55595947265624
      ],
      "confidence": 0.9955737590789795,
      "reading_order": 3
    },
    {
      "element_id": "elem_004_0039",
      "page_num": 4,
      "element_type": "text",
      "bbox": [
        44.27542694091797,
        370.143369140625,
        557.3605078125,
        439.2411328125
      ],
      "confidence": 0.9902216196060181,
      "reading_order": 4,
      "content": "Fig.2 StructuralfeaturesofnativeHAexpressedoninfluenzavirusandrHAproducedininsectcellsusingthebaculovirusexpressio\nvector system. a HA protein (shown as monomer) extracted from influenza virus is a heterodimer comprising HA1 (turquoise) and HA\n(orange)linkedthoughaninter-disulfide(S\u2013S)bondandcontainscomplex-typesialylatedN-linkedglycans.Cleavedfusionpeptides(green\nandcomplexglycans74eliminateandmaskuniqueepitopesonHArespectively.bRecombinantHAprotein(shownasmonomer)expressedi\ninsectcellsasasingleprecursorpolypeptide(HA0)withaminoacidsequenceidenticaltowildtypeHAsequenceandcontainsunsialylate\npaucimannosidic N-linked glycans74. HA0 is coloured in turquoise and orange to show HA1 and HA2 segments combined as a singl\npolypeptide.Uncleavedfusion-peptideloop(green)andsimplerglycanspreserveandexposeuniqueepitopesonrHA."
    },
    {
      "element_id": "elem_004_0040",
      "page_num": 4,
      "element_type": "text",
      "bbox": [
        311.44201171875,
        441.94508789062496,
        555.250078125,
        737.692822265625
      ],
      "confidence": 0.9860806465148926,
      "reading_order": 5,
      "content": "ind near the uncleaved fusion peptide that protrudes at th\nurfaceoftheHA0rosettes.Turneretal.59identifiedamonoclon\nntibodythatbindstoanepitopeonHAmoleculesthatarepartl\nnd transiently exposed in the pre-fusion conformation5\ntructural analysis of the antigen-antibody complex revealed\notential dynamic state where HA undergoes structural fluctu\nions in its pre-fusion state59. A recent study by Khurana et al.\nurther demonstrated, using surface plasmon resonance techno\ngy, that the observed broader specificity of antibodies induce\ny RIV4 may be linked to the presence of unique epitopes o\nA060.Additionally,severalgroupshaveisolated,usingHA0asth\nmmunogenorfromaphagedisplaylibrary,protectiveantibodi\npecific to epitopes in the fusion loop region present only i\nA061,62.Theseantibodiesexhibited unprecedentedbreadthan\notencyandneutralisedadiversepanelofrepresentativevirus\nngroup1andgroup2influenzaA,blockedproteasecleavage\nA0andlockedHAinthepre-fusionstate.Thus,theseantibodi\nake the virus non-infectious by inhibiting the pH-induce\nonformation change and the HA-mediated membrane fusio\nhatareessentialforthevirusinfectivity.HAmoleculespresente\nn influenza virions are predominantly in the pre-fusion stat\nnce the virus binds to a cell or enters the acidic endosome\nnfectedcells,thefusionloopiscleavedtoyieldHA1andHA2,an\nhe hydrophobic fusion peptide in the N-terminus of HA2\nequestered away from membranes in a pocket, limiting i\nxposure52,63.Nonetheless,itwouldbeofinteresttoexamineth\nmmunogenicityofreleasedHAfusionpeptidesinthepost-fusio\ntateandtheirpotentialroleinprotection,asthesearepresenti\nonventional influenza vaccines. Together, these critical findin"
    },
    {
      "element_id": "elem_005_0041",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        36.35095275878906,
        606.0482666015624,
        283.1363525390625,
        735.7775097656249
      ],
      "confidence": 0.9940621256828308,
      "reading_order": 1,
      "content": "In Canada between 2000 and 2004, an unusual number o\nasesofasyndrometermedasoculo-respiratorysyndrome(ORS\nere reported following immunisation with the inactivate\nnfluenza split-virus vaccine68. Detailed analysis revealed tha\nRS, induced within 2 to 24h of vaccination, was suspected t\neduetothepresenceofmicro-aggregatesofunsplitvirionsi\nheconventionalegg-derivedinfluenzavaccines69.Highlevelso\nggregate content in the split vaccine are believed to hav\nnduced a Type-2 polarised immune response resulting in OR\nased on study results from a mouse model70. Althoug\nxtremely rare, this is unlikely to occur with RIV4 that contain\nA rosettes of small and uniform size."
    },
    {
      "element_id": "elem_005_0042",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        35.208075256347655,
        502.059814453125,
        283.1239819335937,
        607.4204589843749
      ],
      "confidence": 0.9945138692855835,
      "reading_order": 2,
      "content": "Further characterisation by cryo-electron microscopy ha\nrevealed that the HA rosette clusters in RIV4 are uniforml\nstarfish-shaped;whereasinthesplitvaccinetheyaremostlynon\nsymmetrical and agglomerated into huge structures, resulting i\nboth starfish- and peanut-shaped heterogeneous particles55\nAdditional electron microscopy analysis of split vaccine cluster\nshowed a highly heterogeneous mixture containing differen\ntypesofviralparticlescontainingHAandNAaswellassplitvira\nmembranefoldedinvariousshapes,slightlydisruptedvirions,an\n66"
    },
    {
      "element_id": "elem_005_0043",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        37.065292053222656,
        366.37185058593747,
        282.0563525390625,
        503.10228515625
      ],
      "confidence": 0.9897176027297974,
      "reading_order": 3,
      "content": "s described above, HA is expressed on the viral surface as a H\nrimer (rosette). When these are extracted from influenza viruse\nhey form clusters of varying sizes. This has been observed i\nonventionalinfluenzavirus-derivedvaccines,withestimatesof1\no 1100 trimers per cluster55,66,67. Two distinct populations o\nlusterhavebeenobserved;themajorityhaveanaveragediamete\nf 150nm, while the remainder are larger (average diamete\n500nm)66.However,therosetteclustersinRIV4areuniforminsiz\nnd presentation, containing around six to eight HA trimers pe\nlusteratanaveragediameterofapproximately30\u201340nm55,67.Th\nlution of rHA from RIV4 drug substance as a single peak in size\nxclusion high-performance liquid chromatography is monitore"
    },
    {
      "element_id": "elem_005_0044",
      "page_num": 5,
      "element_type": "title",
      "bbox": [
        35.81140869140625,
        335.4143115234375,
        283.49830810546877,
        365.23946777343747
      ],
      "confidence": 0.9188194274902344,
      "reading_order": 4,
      "content": "THEHOMOGENEITYOFRECOMBINANTHAANTIGENSINRIV\nMAYIMPROVE THESAFETYPROFILE OVERCONVENTIONAL\nINFLUENZAVACCINES"
    },
    {
      "element_id": "elem_005_0045",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        36.17580322265625,
        97.22513671875,
        286.5204711914062,
        298.7607788085937
      ],
      "confidence": 0.9864022135734558,
      "reading_order": 5,
      "content": "Structural differences in the HA polypeptides and rosettes\netween recombinant and split vaccines have been shown to\nesult in differences, both qualitative and quantitative, in the\nmmune response to vaccines in humans and animals. Portnoff\nt al.64 demonstrated that recombinant HA antigens (specifically\northeH3strain)producedusingBEVS(asusedforRIV4),induced\nignificantly higher levels of broadly cross-reactive antibodies\ngainst highly conserved regions of the HA head and stem\nomains than egg-derived split vaccines64. Recently Richards\nt al.65 examined CD4 T-cell and antibody responses in healthy\ndults who received egg-derived split vaccine, cell-derived split\naccineorRIV4forthreesuccessiveinfluenzaseasons(2015\u20132016,\n016\u20132017, and 2017\u20132018)65. RIV4 elicited the most robust\nesponses,withsignificantlyhigherT-cellandantibodylevelsthan\nheothertwovaccines.Authorspostulatedthatsimplerglycosyla-\nion of rHA and absence of other influenza viral proteins in RIV4\nontributedtotheobservedrobustimmuneresponseforRIV4and\nmphasised the relevance of these features in determining\nfi 65"
    },
    {
      "element_id": "elem_005_0046",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        35.66513122558594,
        58.02353942871093,
        286.1814111328125,
        98.60310791015624
      ],
      "confidence": 0.9610600471496582,
      "reading_order": 6,
      "content": "clearlydemonstrate structural differences betweenHApre-fusion\nand post-fusion states, and the presence of unique neutralising\nepitopes in the pre-fusion HA0 molecules, which are present in"
    },
    {
      "element_id": "elem_005_0047",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        301.18840576171874,
        548.797060546875,
        550.1032470703125,
        735.3944384765625
      ],
      "confidence": 0.9924058318138123,
      "reading_order": 7,
      "content": "RIV4 has a unique ability to induce broadly cross-reactive\nantibody responses to antigenically drifted A/H3N2 viruses in\nhumans. In a small study by Belongia et al.82, participants aged\n65\u201374 years were immunised with RIV4, a high-dose split-virion\ninactivated trivalent influenza vaccine (Fluzone\u00ae High Dose,\nSanofi Pasteur; HD-IIV3) or adjuvanted-IIV3 (aIIV3)82. Participant\nsera were tested against four A/H3N2 viruses including a cell-\npropagated referencevaccinestrain, twocirculatingviruses and\nanantigenicallyadvanced viruswithevidenceofantigenicdrift.\nThe post-vaccination geometric mean fold rise against the two\ncirculating viruses was twice as high for RIV4 as for HD-IIV3 or\naIIV3. Post-vaccination titre against the antigenically drifted\nH3N2weregenerallylowandsimilaracrossallgroups,however,\nreceipt of RIV4 was strongly associated with seroconversion to\nthisstrain(p=0.003).Theinvestigatorssuggestedthatalthough\nthe circulating A/H3N2 viruses were antigenically similar to the\ncell-grown vaccine reference virus, egg propagation of the\nvaccine strains had led to loss of a glycosylation site and"
    },
    {
      "element_id": "elem_005_0048",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        300.73743896484376,
        399.57552246093746,
        547.407421875,
        550.716064453125
      ],
      "confidence": 0.9970153570175171,
      "reading_order": 8,
      "content": "In a study by Nachbagauer et al.78, RIV4 induced HA stem\nspecificneutralisingantibodiesdirectedagainstinfluenzasubtype\nH1, H3 and B haemagglutinin in an age-dependent manner i\nhumans,withthehighesttitresobservedintheelderly78.RIV4als\ninducesantibodies,inbothhumansandmice,thatarespecifict\nepitopes in the HA head region, at greater proportions than\ntraditional mammalian cell-derived subunit vaccine (Flucelvax\n[Trivalent])77. Higher magnitudes of haemagglutination inhibitor\nantibodyresponseagainstHA1havealsobeenobservedwithRIV\ncompared to egg- or mammalian cell-derived split vaccine\n(Flucelvax\u00ae Tetra, Seqirus, and Fluzone\u00ae quadrivalent SD, Sano\nPasteur)60.Thesedatawarrantadditionalstudiestoverifywhethe\nrHA elicits a broader antibody repertoire than convention\nvaccines and whether this underlies the cross-protection agains\n12,81"
    },
    {
      "element_id": "elem_005_0049",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        303.173349609375,
        236.40958740234373,
        548.0217773437499,
        401.0730029296875
      ],
      "confidence": 0.9957446455955505,
      "reading_order": 9,
      "content": "The peptide sequences around glycosylation sites are highl\nonservedand,assuch,antibodiesdirectedagainsttheseregion\nould provide broader specificity. Antisera raised against simpl\nonoglycosylatedHAinmicewereshowntoimprovethebreadt\nnd capacity of HA-neutralising antibodies to protect agains\nethal challenge with H5N1 compared to antisera raised agains\nully glycosylated HA75. Thus, elimination of parts of glycans tha\nre not essential for HA structure may improve vaccine-induce\nrotection. Subsequent studies showed that HA with simple\nlycans induce more broadly protective antibodies with superio\nross-clade protection compared to HA with more comple\nlycans76\u201379. The presence of simpler glycans appears to b\nqually efficient to that of chicken or mammalian cell-derive\nlycosylation in ensuring the proper folding of HA, and expose\nonservedregionsofthemoleculefortheinductionofimmunit\n12,71,76\u201380"
    },
    {
      "element_id": "elem_005_0050",
      "page_num": 5,
      "element_type": "text",
      "bbox": [
        302.72625,
        84.34361206054687,
        549.2882373046875,
        240.71675537109374
      ],
      "confidence": 0.9911256432533264,
      "reading_order": 10,
      "content": "nfluenzaHAhasavariablenumberofN-linkedglycosylationsite\ndependingonthevirusstrainandsubtype)intheglobularhea\negionandtheconservedstemregion71.TheglycosylationofH\nas various functions, including regulation of the virus life-cycl\nndaroleindiseasepathogenesis71.Duringvaccinemanufacture\nhe host cells used for the production of HA play a major role i\netermining HA N-glycan composition72,73. Glycoprotein\nxpressed in mammalian cells typically have sialylated complex\nype N-linked glycans, while those expressed in insect cell\nypically have simple unsialylated glycans (either truncated\naucimannosidic or oligomannosidic glycans)74. An et al.7\nhowed that egg-derived and mammalian (Madin-Darby canin\nidney)cell-derivedHApredominantlycontainedhighly-branche\nomplex or high-mannose glycans, whereas HA expressed in Sf\nnsectcells had relativelysmallpaucimannose glycans (Fig. 2)72."
    },
    {
      "element_id": "elem_005_0051",
      "page_num": 5,
      "element_type": "title",
      "bbox": [
        299.89037109375,
        56.7614794921875,
        545.5100830078125,
        87.03180725097656
      ],
      "confidence": 0.9655909538269043,
      "reading_order": 11,
      "content": "THEN-LINKED GLYCAN STRUCTUREOFRECOMBINANT HA\nPRODUCED ININSECT CELLS DIFFERS SIGNIFICANTLY FROM\nHAINOTHERINFLUENZA VACCINES"
    },
    {
      "element_id": "elem_006_0052",
      "page_num": 6,
      "element_type": "title",
      "bbox": [
        44.721430664062495,
        702.6099169921874,
        104.87681762695313,
        713.634169921875
      ],
      "confidence": 0.9971299767494202,
      "reading_order": 1,
      "content": "CONCLUSIONS"
    },
    {
      "element_id": "elem_006_0053",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        43.785129089355465,
        715.657060546875,
        294.8968212890625,
        735.8655322265624
      ],
      "confidence": 0.9649184346199036,
      "reading_order": 2,
      "content": "The evidence reviewed here demonstrates several advantages of\nthe BEVS used in the manufacture of RIV4 over conventional"
    },
    {
      "element_id": "elem_006_0054",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        45.863709411621095,
        594.3571435546875,
        294.6070239257812,
        684.7966845703124
      ],
      "confidence": 0.9977753758430481,
      "reading_order": 3,
      "content": "Although uncommon, some individuals may be at increased\nisk of hypersensitivity reactions to component proteinssuchas\nvalbuminandthosewhoaresensitisedmaybeathigherriskof\nlinical manifestations of allergic disease upon exposure92. Egg\nrotein, viral RNA, and process impurities such as inactivating\ngents or hydrocortisone that are typically present in conven-\nional vaccines are absent in RIV4 would eliminate potential\ndverse reactions, although rare, to these components in\nulnerable individuals93."
    },
    {
      "element_id": "elem_006_0055",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        45.05977111816406,
        465.62910644531246,
        293.1829541015625,
        596.8121044921875
      ],
      "confidence": 0.9941898584365845,
      "reading_order": 4,
      "content": "As most split and subunit vaccines are prepared from in uenz\nvirusesthataregrowninembryonatedchickeneggs,theycontai\negg proteins. Testing of 58 vaccine lots covering six differen\nseasonal influenza vaccines produced by five different manufac\nturers showed that the median ovalbumin concentration wa\n350ng/mL89. Moreover, another study of commercial influenz\nvaccine preparations detected other viral proteins such a\nnucleoprotein and matrix protein (confirmed by a chromato\ngraphicseparation)thatarenotshowntoberelevantforvaccin\neffectiveness, and viral RNA fragments (confirmed by activit\nassay)90,91. Such egg-derived or other influenza virus-derive\nproteins (as described above) and influenza viral RNA fragment\narenot present inrecombinant vaccines."
    },
    {
      "element_id": "elem_006_0056",
      "page_num": 6,
      "element_type": "title",
      "bbox": [
        45.71754180908203,
        433.43995605468746,
        293.377236328125,
        463.6290673828125
      ],
      "confidence": 0.9584028720855713,
      "reading_order": 5,
      "content": "BSENCEOFEGGOROTHERINFLUENZAVIRALCOMPONENTS\nNRECOMBINANT HA VACCINE ISLIKELY TO FAVOUR ITS"
    },
    {
      "element_id": "elem_006_0057",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        45.538530578613276,
        316.020234375,
        294.84613037109375,
        415.54604003906246
      ],
      "confidence": 0.9683619737625122,
      "reading_order": 6,
      "content": "nallconventionalin uenzavaccines,whetherderivedfromeggs\nr mammalian cells, the antigens are exposed to inactivation\ngents such as formaldehyde or \u03b2-propiolactone (BPL). These\nnactivatingagentscausenumerousmodificationstotheantigenic\npitopesonHAthroughcross-linkingorformationofbis-alkylated\nroups85\u201387.Thesemodificationsoftenresultinchangestoprotein\nolding, conformation, and stability88. Unlike conventional vac-\nines, RIV4 does not go through an inactivation step, thus\nreserving the native HA conformation of the wild-type virus,"
    },
    {
      "element_id": "elem_006_0058",
      "page_num": 6,
      "element_type": "title",
      "bbox": [
        46.4923828125,
        294.08561279296873,
        272.50925537109373,
        315.16677246093747
      ],
      "confidence": 0.9940453767776489,
      "reading_order": 7,
      "content": "ECOMBINANTHA ANTIGENSARENOT SUBJECTED TO\nHEMICALMODIFICATIONS"
    },
    {
      "element_id": "elem_006_0059",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        45.55305725097656,
        73.37817993164062,
        294.63662109374997,
        276.20299072265624
      ],
      "confidence": 0.9614008665084839,
      "reading_order": 8,
      "content": "Inadditionto the above referenced studies,ina recent study\ny Shinde et al.83 baculovirus-expressed rHA generated cross-\nrotective responses against both circulating and drifted\n/H3N2 strains, including in older adults who are at a higher\niskforinfluenzaandassociatedmedicalcomplications83,84.This\nniquecharacteristicoftherecombinantvaccineislikelyrelated\noglycosylationofrHAintheinsectcellline,leavingituncleaved.\nhe higher quantity and greater accessibility of the genetically\nonservedstemregionofrHAproducedininsectcells(resulting\nn smaller N-linked glycans) may contribute to cross-protection\ngainstmismatchedinfluenzastrains12,75.Thestudy by Nachba-\naeur et al.78 supports the hypothesis that a recombinant\naccineresultsinincreasedtitreofbroadlyneutralisingHAstem-\neactive antibodies and that these immune responses increase\nith age78. This increase with age is possibly due to repeated\nxposuretodivergentinfluenzavirusessimilartothemultipleA/\n3N2 virus strains evaluated by Belongia et al.82. Therefore,\naccine constructs that preserve the highly conserved HA stem\nanprotectagainstdriftedvirusesandthusmayconferagreater\nfl"
    },
    {
      "element_id": "elem_006_0060",
      "page_num": 6,
      "element_type": "title",
      "bbox": [
        44.51585723876953,
        58.336765136718746,
        295.7469873046875,
        77.497119140625
      ],
      "confidence": 0.6234096884727478,
      "reading_order": 9,
      "content": "with previous reports26."
    },
    {
      "element_id": "elem_006_0061",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        43.47267242431641,
        58.48276245117187,
        291.59402343749997,
        77.26831237792969
      ],
      "confidence": 0.7472254037857056,
      "reading_order": 10,
      "content": "with previous reports26."
    },
    {
      "element_id": "elem_006_0062",
      "page_num": 6,
      "element_type": "title",
      "bbox": [
        311.44350585937497,
        335.59995849609373,
        361.82335693359374,
        345.64928466796874
      ],
      "confidence": 0.978653073310852,
      "reading_order": 11,
      "content": "EFERENCES"
    },
    {
      "element_id": "elem_006_0063",
      "page_num": 6,
      "element_type": "title",
      "bbox": [
        311.7868505859375,
        254.60624267578123,
        392.5760888671875,
        265.2382177734375
      ],
      "confidence": 0.9969758987426758,
      "reading_order": 12,
      "content": "ATAAVAILABILITY"
    },
    {
      "element_id": "elem_006_0064",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        312.0809545898437,
        287.3136840820312,
        517.2846240234375,
        308.33549560546874
      ],
      "confidence": 0.9295899868011475,
      "reading_order": 13,
      "content": "eceived:24May2021; Accepted: 3November 2021"
    },
    {
      "element_id": "elem_006_0065",
      "page_num": 6,
      "element_type": "title",
      "bbox": [
        309.91581298828123,
        266.90934814453124,
        447.21382324218746,
        276.29369384765624
      ],
      "confidence": 0.9608618021011353,
      "reading_order": 14,
      "content": "Nodataweregeneratedforthereviewarticl"
    },
    {
      "element_id": "elem_006_0066",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        314.8402368164062,
        715.3577490234375,
        559.8282568359375,
        733.2585205078125
      ],
      "confidence": 0.6996215581893921,
      "reading_order": 15,
      "content": "7. Tricco,A.C.etal.Comparingin uenzavaccineef cacyagainstmismatchedand\nmatchedstrains:asystematicreviewandmeta-analysis.BMCMed.11,153(2013)."
    },
    {
      "element_id": "elem_006_0067",
      "page_num": 6,
      "element_type": "list",
      "bbox": [
        306.43701416015625,
        354.14123291015625,
        561.704677734375,
        726.760810546875
      ],
      "confidence": 0.9892112016677856,
      "reading_order": 16,
      "content": "mortality:amodellingstudy.Lancet391,1285\u20131300(2018).\n2. WorldHealthOrganization.Fact-sheet.Influenza(Seasonal).Availableathttps://\nwww.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).Accessed12\nMarch2021.(2018).\n3. Lafond,K.E.etal.Globalburdenofinfluenza-associatedlowerrespiratorytract\ninfections and hospitalizations among adults: a systematic review and meta-\nanalysis.PLoSMed.18,e1003550(2021).\n4. US Centers for Disease Control and Prevention (CDC). Weekly U.S. Influenza\nSurveillance Report. https://www.cdc.gov/flu/weekly/index.htm. Accessed 16\nMarch2021.\n5. Sellers,S.A.,Hagan,R.S.,Hayden,F.G.&Fischer,W.A.IIThehiddenburdenof\ninfluenza:areviewoftheextra-pulmonarycomplicationsofinfluenzainfection.\nInfluenzaOtherRespir.Viruses11,372\u2013393(2017).\n6. deFranciscoShapovalova,N.,Donadel,M.,Jit,M.&Hutubessy,R.Asystematic\nreview of the social and economic burden of influenza in low- and middle-\nincomecountries.Vaccine33,6537\u20136544(2015).\n7. Szucs,T.Thesocio-economicburdenofinfluenza.J.Antimicrob.Chemother.44\nSupplB,11\u201315(1999).\n8. Krammer,F.etal.Influenza.Nat.Rev.Dis.Prim.4,3(2018).\n9. Paules,C.&Subbarao,K.Influenza.Lancet390,697\u2013708(2017).\n10. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum\nhaemagglutination-inhibitingantibodyinprotectionagainstchallengeinfection\nwithinfluenzaA2andBviruses.Epidemiol.Infect.70,767\u2013777(1972).\n11. Ohmit,S.E.etal.Influenzahemagglutination-inhibitionantibodytiterasacor-\nrelateofvaccine-inducedprotection.J.Infect.Dis.204,1879\u20131885(2011).\n12. Dunkle,L.M.etal.Efficacyofrecombinantinfluenzavaccineinadults50yearsof\nageorolder.N.Engl.J.Med.376,2427\u20132436(2017).\n13. Wohlbold,T.J.&Krammer,F.Intheshadowofhemagglutinin:agrowinginterest\nin influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6,\n2465\u20132494(2014).\n14. Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Influenza\nneuraminidase:aneglectedproteinanditspotentialforabetterinfluenzavac-\ncine.Vaccines8,409(2020).\n15. WorldHealthOrganization.GlobalInfluenzaSurveillanceandResponseSystem\n(GISRS). Available at https://www.who.int/influenza/gisrs_laboratory/en/. Acces-\nsed17February2021.(2021).\n16. Camilloni,B.,Neri,M.,Lepri,E.&Iorio,A.M.Cross-reactiveantibodiesinmiddle-\nagedandelderlyvolunteersafterMF59-adjuvantedsubunittrivalentinfluenza\nvaccineagainstBvirusesoftheB/VictoriaorB/Yamagatalineages.Vaccine27,\n4099\u20134103(2009).\n17. Tricco,A.C.etal.Comparinginfluenzavaccineefficacyagainstmismatchedand"
    },
    {
      "element_id": "elem_006_0068",
      "page_num": 6,
      "element_type": "text",
      "bbox": [
        310.41509765625,
        58.06283203125,
        560.1719970703125,
        236.82287109375
      ],
      "confidence": 0.9835387468338013,
      "reading_order": 17,
      "content": "in uenzavaccinesthatrelyonin uenzavirionspropagatedinegg\normammaliancells,splitwithdetergentswithorwithoutfurtherHA\nenrichment.Theuseofrecombinantproteintechnologyeliminates\ntheriskofantigenicmismatchduetopotentialchangesinprimary\nHA structure through egg- or cell-adaptation. We also describe\nfeaturesoftherHAtertiarystructurethatarelikelytoberesponsible\nforthegenerationofbroadcross-reactiveandprotectiveantibodies,\ntogether with the direct or indirect evidence supporting this. The\nhomogeneity of rHA rosettes and negligible process-related\nimpurities are the hallmarks of RIV4. As rHA production bypasses\nthe need for a viral inactivation step and avoids the use of eggs,\nrelated process-impurities such as inactivating agents or residual\negg-protein, and thus potential adverse reactions to these\nimpurities in vulnerable individuals are eliminated. This well-\nestablished and validated platform for vaccine manufacture could\nbeextended to addressotheremerging infectious diseaseswhere\ncross-protectionagainstconstantlyevolvingvariantsiscritical,such\naspandemicinfluenzaand/orCOVID-19."
    },
    {
      "element_id": "elem_007_0069",
      "page_num": 7,
      "element_type": "list",
      "bbox": [
        34.23059143066406,
        228.61193115234374,
        283.99352783203125,
        719.768935546875
      ],
      "confidence": 0.8955439925193787,
      "reading_order": 1,
      "content": "with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in\ncirculatingviruses.PLoSONE9,e92153(2014).\n26. Zost,S.J.etal.ContemporaryH3N2influenzaviruseshaveaglycosylationsite\nthataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains.Proc.\nNatlAcad.Sci.USA114,12578\u201312583(2017).\n27. Flannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine\neffectiveness-UnitedStates,February2017.MMWRMorb.Mortal.WklyRep.66,\n167\u2013171(2017).\n28. Shu,Y.&McCauley,J.GISAID:Globalinitiativeonsharingallinfluenzadata-from\nvisiontoreality.Eurosurveillance:bulletinEuropeensurlesmaladiestransmis-\nsibles = European communicable disease bulletin 22, https://doi.org/10.2807/\n1560-7917.Es.2017.22.13.30494(2017).\n29. Song,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield\nbacterial expression: a solution to global pandemic and seasonal needs. PLoS\nONE3,e2257(2008).\n30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent\nseasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion\nproteins.OpenForumInfect.Dis.3,ofw015(2016).\n31. Aguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine\nproducedinEscherichiacoli.PLoSONE5,e11694(2010).\n32. Saczynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in\nbacteria.ActaBiochimPol.61,561\u2013572(2014).\n33. Davis, A. R. et al. Immune response to human influenza virus hemagglutinin\nexpressedinEscherichiacoli.Gene21,273\u2013284(1983).\n34. Rosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe\nfightagainstCOVID-19?Vaccines8,183(2020).\n35. Pillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine\ninduces cross-reactive antibody and T cell response in healthy adults. Clin.\nImmunol.168,72\u201387(2016).\n36. Pillet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus\nlikeparticleinfluenzavaccinecandidate-tworandomizedPhaseIIclinicaltrialsin\n18to49and>/=50yearsoldadults.PLoSONE14,e0216533(2019).\n37. Ward,B.J.etal.Efficacy,immunogenicity,andsafetyofaplant-derived,quad-\nrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older\nadults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396,\n1491\u20131503(2020).\n38. Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant-\nderived virus-like particles bearing influenza hemagglutinin. Vaccine 36,\n8028\u20138038(2018).\n39. Pandey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu-\nnogenicityandprotectionconferredwithanadenovirus-basedH5N1influenza\nvaccine.PLoSONE7,e33428\u2013e33428(2012).\n40. Sayedahmed, E. E. etal.Adenoviral vector-based vaccine platforms for devel-\nopingthenextgenerationofinfluenzavaccines.Vaccines8,574(2020).\n41. Xiang, K. et al. Progress on adenovirus-vectored universal influenza vaccines.\nHum.VaccinImmunother.11,1209\u20131222(2015).\n42. Chen,J.R.etal.Betterinfluenzavaccines:anindustryperspective.J.Biomed.Sci.\n27,33(2020).\n43. Report to the president on reengeneering the influenza vaccine production\nenterprisetomeetthechallengesofpandemicinfluenza.Availableathttps://\nobamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST-\nInfluenza-Vaccinology-Report.pdf.AccessedAugust2021.\n44. L\u00f3pez-Mac\u00edas,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan-\ndemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-"
    },
    {
      "element_id": "elem_007_0070",
      "page_num": 7,
      "element_type": "list",
      "bbox": [
        33.785266113281246,
        69.980888671875,
        283.9118994140625,
        473.15724609374996
      ],
      "confidence": 0.8753602504730225,
      "reading_order": 2,
      "content": "(2018).\n19. Sautto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza\nvaccine:differentapproachesforonegoal.Virol.J.15,17(2018).\n20. Nachbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus\nvaccine approach induces broad and long-lasting immunity in a randomized,\nplacebo-controlledphaseItrial.Nat.Med.27,106\u2013114(2021).\n21. Orenstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro-\nduction,distribution,supply,anddemand\u2013whatitmeansfortheprovider.Am.J\nMed.121,S22\u2013S27(2008).\n22. Felberbaum, R. S. The baculovirus expression vector system: a commercia\nmanufacturingplatformforviralvaccinesandgenetherapyvectors.Biotechnol.J\n10,702\u2013714(2015).\n23. Cox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect\ncells.J.Invertebr.Pathol.107,S31\u2013S41(2011).\n24. Raymond,D.D.etal.Influenzaimmunizationelicitsantibodiesspecificforan\negg-adaptedvaccinestrain.Nat.Med.22,1465\u20131469(2016).\n25. Skowronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated\nwith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift i\ncirculatingviruses.PLoSONE9,e92153(2014).\n26. Zost,S.J.etal.ContemporaryH3N2influenzaviruseshaveaglycosylationsit\nthataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains.Proc.\nNatlAcad.Sci.USA114,12578\u201312583(2017).\n27. Flannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine\neffectiveness-UnitedStates,February2017.MMWRMorb.Mortal.WklyRep.66\n167\u2013171(2017).\n28. Shu,Y.&McCauley,J.GISAID:Globalinitiativeonsharingallinfluenzadata-from\nvisiontoreality.Eurosurveillance:bulletinEuropeensurlesmaladiestransmis-\nsibles = European communicable disease bulletin 22, https://doi.org/10.2807/\n1560-7917.Es.2017.22.13.30494(2017).\n29. Song,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield\nbacterial expression: a solution to global pandemic and seasonal needs. PLoS\nONE3,e2257(2008).\n30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent\nseasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion\nproteins.OpenForumInfect.Dis.3,ofw015(2016).\n31. Aguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine\nproducedinEscherichiacoli.PLoSONE5,e11694(2010).\n32. Saczynska, V.Influenzavirus hemagglutinin asavaccine antigen produced i\nbacteria.ActaBiochimPol.61,561\u2013572(2014).\n33. Davis, A. R. et al. Immune response to human influenza virus hemagglutinin\nexpressedinEscherichiacoli.Gene21,273\u2013284(1983).\n34. Rosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertoth\nfightagainstCOVID-19?Vaccines8,183(2020).\n35. Pillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine"
    },
    {
      "element_id": "elem_007_0071",
      "page_num": 7,
      "element_type": "list",
      "bbox": [
        51.437180786132814,
        63.77546447753906,
        467.70644531249997,
        730.83779296875
      ],
      "confidence": 0.6247051358222961,
      "reading_order": 3,
      "content": "efinedbyavaccine-inducedantibody.Proc.NatlAcad.Sci.USA115,168\u2013173 ticlevaccine.Biopharm.Int23Suppl10,26\u201334(20\n018). 46. Fernandes,F.etal.Insectcellsasaproductionpl\nutto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza particles.ExpertRev.Vaccines12,225\u2013236(2013).\nccine:differentapproachesforonegoal.Virol.J.15,17(2018). 47. Influenza vaccine strategies for broad global acce\nachbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus azureedge.net/media/documents/VAC_infl_publ_rpt_\nccine approach induces broad and long-lasting immunity in a randomized, 2021.\nlacebo-controlledphaseItrial.Nat.Med.27,106\u2013114(2021). 48. European Medicines Agency. Assessment report.\nrenstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro- EMEA/H/C/005159/0000. Available at https://www.e\nuction,distribution,supply,anddemand\u2013whatitmeansfortheprovider.Am.J. assessment-report/supemtek-epar-public-assessment-\ned.121,S22\u2013S27(2008). February2021.\nlberbaum, R. S. The baculovirus expression vector system: a commercial 49. HealthCanada.RegisterofInnovativeDrugs[Upda\nanufacturingplatformforviralvaccinesandgenetherapyvectors.Biotechnol.J. from https://www.canada.ca/en/health-canada/ser\n0,702\u2013714(2015). drug-products/applications-submissions/register-inn\nox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect sed19April2021.\nlls.J.Invertebr.Pathol.107,S31\u2013S41(2011). 50. Taubenberger, J.K.Influenzavirus hemagglutinin\naymond,D.D.etal.Influenzaimmunizationelicitsantibodiesspecificforan laughingmatter.Proc.NatlAcad.Sci.USA95,9713\u2013\ng-adaptedvaccinestrain.Nat.Med.22,1465\u20131469(2016). 51. Stieneke-Gr\u00f6ber,A.etal.Influenzavirushemaggluti\nowronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated siteisactivatedbyfurin,asubtilisin-likeendoprote\nith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in (1992).PMC556715.\nrculatingviruses.PLoSONE9,e92153(2014). 52. Chen,J.etal.Structureofthehemagglutininprec\nost,S.J.etal.ContemporaryH3N2influenzaviruseshaveaglycosylationsite minantofinfluenzapathogenicityandtheoriginof\nataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains.Proc. 95,409\u2013417(1998).\natlAcad.Sci.USA114,12578\u201312583(2017). 53. Luczo,J.M.etal.MolecularpathogenesisofH5hi\nannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine enza: the role of the haemagglutinin cleavage sit\nfectiveness-UnitedStates,February2017.MMWRMorb.Mortal.WklyRep.66, 406\u2013430(2015).\n7\u2013171(2017). 54. Boonstra, S. et al. Hemagglutinin-mediated mem\nu,Y.&McCauley,J.GISAID:Globalinitiativeonsharingallinfluenzadata-from perspective.AnnuRev.Biophys.47,153\u2013173(2018).\nsiontoreality.Eurosurveillance:bulletinEuropeensurlesmaladiestransmis- 55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Charact\nbles = European communicable disease bulletin 22, https://doi.org/10.2807/ hemagglutinin complexes by cryo-electron micro\n60-7917.Es.2017.22.13.30494(2017). revealsstructuralpolymorphisms.Clin.Vaccin.Imm\nng,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield 56. Kost,T.A.&Condreay,J.P.Recombinantbaculoviru\nacterial expression: a solution to global pandemic and seasonal needs. PLoS insectandmammaliancells.Curr.Opin.Biotechnol.\nNE3,e2257(2008). 57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Chang\nssey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent hemagglutininmoleculeofH3influenzavirusatacid\nasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion (1983).\nroteins.OpenForumInfect.Dis.3,ofw015(2016). 58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationof\nguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine broadly cross-reactive antibodies. Curr. Top. Micro\nroducedinEscherichiacoli.PLoSONE5,e11694(2010). (2015).\nczynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in 59. Turner,H.L.etal.Potentanti-influenzaH7human\nacteria.ActaBiochimPol.61,561\u2013572(2014). separation of hemagglutinin receptor-binding he\navis, A. R. et al. Immune response to human influenza virus hemagglutinin e3000139(2019).\npressedinEscherichiacoli.Gene21,273\u2013284(1983). 60. Khurana,S.etal.Repeatvaccinationreducesantibo\nosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe differentinfluenzavaccineplatformsinhumans.Na\nghtagainstCOVID-19?Vaccines8,183(2020). 61. Ekiert, D. C. et al. Antibody recognition of a highl\nillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine epitope.Science324,246\u2013251(2009).\nduces cross-reactive antibody and T cell response in healthy adults. Clin. 62. Kallewaard,N.L.etal.Structureandfunctionanalysi\nmunol.168,72\u201387(2016). allinfluenzaAsubtypes.Cell166,596\u2013608(2016).\nillet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus 63. Benhaim, M. A. etal. Structural monitoring of a tr\neparticleinfluenzavaccinecandidate-tworandomizedPhaseIIclinicaltrialsin hemagglutininfusionmachineryoninfluenzavirions\nto49and>/=50yearsoldadults.PLoSONE14,e0216533(2019). 64. Portnoff,A.D.etal.Influenzahemagglutininnanop\nard,B.J.etal.Efficacy,immunogenicity,andsafetyofaplant-derived,quad- neutralizingantibodiesagainststructurallydistinctd\nvalent, virus-like particle influenza vaccine in adults (18-64 years) and older 8,99(2020).\nults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396, 65. Richards,K.A.etal.RecombinantHA-basedvaccin\n91\u20131503(2020). unit vaccines in elicitation of influenza-specific C\non, S. Y. et al. Characterization of the innate stimulatory capacity of plant- dependentantibodyresponsesinhumans.NPJVac\nerived virus-like particles bearing influenza hemagglutinin. Vaccine 36, 66. Tay,T.etal.Investigationintoalternativetestingme\n28\u20138038(2018). tionofinfluenzavirusvaccine.Hum.VaccinesImmun\nandey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu- 67. Gallagher, J. R. et al. Characterization of hemaggl\nogenicityandprotectionconferredwithanadenovirus-basedH5N1influenza virus and within vaccines using electron microsco\nccine.PLoSONE7,e33428\u2013e33428(2012). 10.3390/vaccines6020031(2018).\nyedahmed, E. E. etal.Adenoviral vector-based vaccine platforms for devel- 68. PublicHealthAgencyofCanada.Oculo-respiratorys\npingthenextgenerationofinfluenzavaccines.Vaccines8,574(2020). vaccination:reviewofpost-marketing surveillance\niang, K. et al. Progress on adenovirus-vectored universal influenza vaccines. sonsinCanada.Can.Commun.Dis.Rep.31,217\u201322\num.VaccinImmunother.11,1209\u20131222(2015). 69. Choudhri,Y.&Walop,W.Influenzavaccine-associat\nhen,J.R.etal.Betterinfluenzavaccines:anindustryperspective.J.Biomed.Sci. passive surveillance, Canada 2001-2002. Can. Com\n7,33(2020). (2002).\neport to the president on reengeneering the influenza vaccine production 70. Babiuk,S.etal.AggregatecontentinfluencestheT\nterprisetomeetthechallengesofpandemicinfluenza.Availableathttps:// influenzavaccine:evidencefromamousemodel.J.\nbamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST- 71. Wei,C.J.etal.Cross-neutralizationof1918and20\nfluenza-Vaccinology-Report.pdf.AccessedAugust2021. glycansinviralevolutionandvaccinedesign.Sci.T\npez-Mac\u00edas,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan- 72. An, Y. et al. N-glycosylation of seasonal influen\nemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo- implicationforpotencytestingandimmuneproce\nntrolledtrialofadultsinMexico.Vaccine29,7826\u20137834(2011). 10.1128/JVI.01693-18(2019)."
    },
    {
      "element_id": "elem_007_0072",
      "page_num": 7,
      "element_type": "list",
      "bbox": [
        299.167734375,
        308.5583862304687,
        549.54439453125,
        714.571435546875
      ],
      "confidence": 0.7934908866882324,
      "reading_order": 4,
      "content": "55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Characterizationofinfluenzavaccin\nhemagglutinin complexes by cryo-electron microscopy and image analyse\nrevealsstructuralpolymorphisms.Clin.Vaccin.Immunol.23,483\u2013495(2016).\n56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfo\ninsectandmammaliancells.Curr.Opin.Biotechnol.10,428\u2013433(1999).\n57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofth\nhemagglutininmoleculeofH3influenzavirusatacidicpH.Virology126,587\u201359\n(1983).\n58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedb\nbroadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323\u201334\n(2015).\n59. Turner,H.L.etal.Potentanti-influenzaH7humanmonoclonalantibodyinduce\nseparation of hemagglutinin receptor-binding head domains. PLoS Biol. 17\ne3000139(2019).\n60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacros\ndifferentinfluenzavaccineplatformsinhumans.Nat.Commun.10,3338(2019)\n61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza viru\nepitope.Science324,246\u2013251(2009).\n62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizin\nallinfluenzaAsubtypes.Cell166,596\u2013608(2016).\n63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in th\nhemagglutininfusionmachineryoninfluenzavirions.Sci.Adv.6,eaaz8822(2020)\n64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadl\nneutralizingantibodiesagainststructurallydistinctdomainsofH3N2HA.Vaccine\n8,99(2020).\n65. Richards,K.A.etal.RecombinantHA-basedvaccineoutperformssplitandsub\nunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell\ndependentantibodyresponsesinhumans.NPJVaccines5,77(2020).\n66. Tay,T.etal.Investigationintoalternativetestingmethodologiesforcharacteriza\ntionofinfluenzavirusvaccine.Hum.VaccinesImmunother.11,1673\u20131684(2015).\n67. Gallagher, J. R. et al. Characterization of hemagglutinin antigens on influenz\nvirus and within vaccines using electron microscopy. Vaccines https://doi.org\n10.3390/vaccines6020031(2018).\n68. PublicHealthAgencyofCanada.Oculo-respiratorysyndromefollowinginfluenz\nvaccination:reviewofpost-marketing surveillance throughfourinfluenza sea\nsonsinCanada.Can.Commun.Dis.Rep.31,217\u2013225(2005).\n69. Choudhri,Y.&Walop,W.Influenzavaccine-associatedadverseevents:resultso\npassive surveillance, Canada 2001-2002. Can. Commun. Dis. Rep. 28, 189\u201319\n(2002).\n70. Babiuk,S.etal.AggregatecontentinfluencestheTh1/Th2immuneresponset\ninfluenzavaccine:evidencefromamousemodel.J.Med.Virol.72,138\u2013142(2004)\n71. Wei,C.J.etal.Cross-neutralizationof1918and2009influenzaviruses:roleo\nglycansinviralevolutionandvaccinedesign.Sci.Transl.Med.2,24ra21(2010).\n72. An, Y. et al. N-glycosylation of seasonal influenza vaccine hemagglutinins\nimplicationforpotencytestingandimmuneprocessing.JVirol.https://doi.org"
    },
    {
      "element_id": "elem_007_0073",
      "page_num": 7,
      "element_type": "list",
      "bbox": [
        299.43529541015624,
        64.42852478027343,
        553.8532763671875,
        532.3088232421875
      ],
      "confidence": 0.8876444697380066,
      "reading_order": 5,
      "content": "ticlevaccine.Biopharm.Int23Suppl10,26\u201334(2010).\n46. Fernandes,F.etal.Insectcellsasaproductionplatformofcomplexvirus-like\nparticles.ExpertRev.Vaccines12,225\u2013236(2013).\n47. Influenza vaccine strategies for broad global access. Available at https://path.\nazureedge.net/media/documents/VAC_infl_publ_rpt_10-07.pdf. Accessed August\n2021.\n48. European Medicines Agency. Assessment report. Supemtek. Procedure No.\nEMEA/H/C/005159/0000. Available at https://www.ema.europa.eu/en/documents/\nassessment-report/supemtek-epar-public-assessment-report_en.pdf. Accessed 17\nFebruary2021.\n49. HealthCanada.RegisterofInnovativeDrugs[Updated15April2021].Available\nfrom https://www.canada.ca/en/health-canada/services/drugs-health-products/\ndrug-products/applications-submissions/register-innovative-drugs.html. Acces-\nsed19April2021.\n50. Taubenberger, J.K.Influenzavirus hemagglutinin cleavageintoHA1,HA2:no\nlaughingmatter.Proc.NatlAcad.Sci.USA95,9713\u20139715(1998).\n51. Stieneke-Gr\u00f6ber,A.etal.Influenzavirushemagglutininwithmultibasiccleavage\nsiteisactivatedbyfurin,asubtilisin-likeendoprotease.EMBOJ.11,2407\u20132414\n(1992).PMC556715.\n52. Chen,J.etal.Structureofthehemagglutininprecursorcleavagesite,adeter-\nminantofinfluenzapathogenicityandtheoriginofthelabileconformation.Cell\n95,409\u2013417(1998).\n53. Luczo,J.M.etal.MolecularpathogenesisofH5highlypathogenicavianinflu-\nenza: the role of the haemagglutinin cleavage site motif. Rev. Med Virol. 25,\n406\u2013430(2015).\n54. Boonstra, S. et al. Hemagglutinin-mediated membrane fusion: a biophysical\nperspective.AnnuRev.Biophys.47,153\u2013173(2018).\n55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Characterizationofinfluenzavaccine\nhemagglutinin complexes by cryo-electron microscopy and image analyses\nrevealsstructuralpolymorphisms.Clin.Vaccin.Immunol.23,483\u2013495(2016).\n56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfor\ninsectandmammaliancells.Curr.Opin.Biotechnol.10,428\u2013433(1999).\n57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofthe\nhemagglutininmoleculeofH3influenzavirusatacidicpH.Virology126,587\u2013599\n(1983).\n58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedby\nbroadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323\u2013341\n(2015).\n59. Turner,H.L.etal.Potentanti-influenzaH7humanmonoclonalantibodyinduces\nseparation of hemagglutinin receptor-binding head domains. PLoS Biol. 17,\ne3000139(2019).\n60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacross\ndifferentinfluenzavaccineplatformsinhumans.Nat.Commun.10,3338(2019).\n61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus\nepitope.Science324,246\u2013251(2009).\n62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizing\nallinfluenzaAsubtypes.Cell166,596\u2013608(2016).\n63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in the\nhemagglutininfusionmachineryoninfluenzavirions.Sci.Adv.6,eaaz8822(2020).\n64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadly\nneutralizingantibodiesagainststructurallydistinctdomainsofH3N2HA.Vaccines"
    },
    {
      "element_id": "elem_008_0074",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        48.02065246582031,
        337.8085400390625,
        291.84888427734376,
        362.9873583984375
      ],
      "confidence": 0.5422690510749817,
      "reading_order": 1,
      "content": "seasonalinfluenza\u2014UnitedStates,1976-2007.MMWRMorb.Mortal.WklyRe\n59,1057\u20131062(2010)."
    },
    {
      "element_id": "elem_008_0075",
      "page_num": 8,
      "element_type": "list",
      "bbox": [
        43.23636474609375,
        51.78988037109375,
        290.74792236328125,
        553.52126953125
      ],
      "confidence": 0.9650207757949829,
      "reading_order": 2,
      "content": "73. Schwarzer,J.etal.Glycananalysisincellculture-basedinfluenzavaccinepr\nduction:influenceofhostcelllineandvirusstrainontheglycosylationpattern\nviralhemagglutinin.Vaccine27,4325\u20134336(2009).\n74. Chung,C.Y.etal.SnapShot:N-glycosylationprocessingpathwaysacrosskin\ndoms.Cell171,258\u2013258.e251(2017).\n75. Wang,C.C.etal.Glycansoninfluenzahemagglutininaffectreceptorbindingan\nimmuneresponse.Proc.NatlAcad.Sci.USA106,18137\u201318142(2009).\n76. Chen,J.R.etal.Vaccinationofmonoglycosylatedhemagglutinininducescros\nstrainprotectionagainstinfluenzavirusinfections.Proc.NatlAcad.Sci.USA11\n2476\u20132481(2014).\n77. Henry,C.etal.Monoclonalantibodyresponsesafterrecombinanthemagglutini\nvaccineversussubunitinactivatedinfluenzavirusvaccine:acomparativestudy.\nVirol.https://doi.org/10.1128/JVI.01150-19(2019).\n78. Nachbagauer,R.etal.Agedependenceandisotypespecificityofinfluenzaviru\nhemagglutininstalk-reactiveantibodiesinhumans.mBio7,e01996\u201301915(2016\n79. Reichert,T.etal.Doesglycosylationasamodifieroforiginalantigenicsinexplai\nthecaseagedistributionandunusualtoxicityinpandemicnovelH1N1influenza\nBMCInfect.Dis.10,5(2010).\n80. Wang,K.etal.Expressionandpurificationofaninfluenzahemagglutinin\u2013on\nstep closer to a recombinant protein-based influenza vaccine. Vaccine 2\n2176\u20132185(2006).\n81. Treanor,J.J.etal.Protectiveefficacyofatrivalentrecombinanthemagglutini\nproteinvaccine (FluBlok(R)) against influenzain healthyadults:a randomize\nplacebo-controlledtrial.Vaccine29,7733\u20137739(2011).\n82. Belongia,E.A.etal.Clinicaltrialtoassessimmunogenicityofhigh-dose,adj\nvanted,andrecombinantinfluenzavaccinesagainstcell-grownA(H3N2)viruse\ninadults65to74years,2017-2018.Vaccine38,3121\u20133128(2020).\n83. Shinde,V.etal.Inductionofcross-reactivehemagglutinationinhibitingantibod\nand polyfunctional CD4+ T-cell responses by a recombinant matrix-\nadjuvanted hemagglutinin nanoparticle influenza vaccine. Clin. Infect. Di\nhttps://doi.org/10.1093/cid/ciaa1673(2020).\n84. Centers for Disease Control Prevention. Estimates of deaths associated wit\nseasonalinfluenza\u2014UnitedStates,1976-2007.MMWRMorb.Mortal.WklyRe\n59,1057\u20131062(2010).\n85. Goldstein, M. A. & Tauraso, N. M. Effect of formalin, beta-propiolactone, me\nthiolate,andultravioletlightuponinfluenzavirusinfectivitychickencellaggl\ntination,hemagglutination,andantigenicity.Appl.Microbiol.19,290\u2013294(1970\n86. Uittenbogaard, J. P., Zomer, B., Hoogerhout, P. & Metz, B. Reactions of bet\npropiolactone with nucleobase analogues, nucleosides, and peptides: implic\ntionsfortheinactivationofviruses.J.Biol.Chem.286,36198\u201336214(2011).\n87. She,Y.M.etal.Surfacemodificationsofinfluenzaproteinsuponvirusinactiv\ntionby\u03b2-propiolactone.Proteomics13,3537\u20133547(2013).\n88. Herrera-Rodriguez, J. et al. Inactivated or damaged? Comparing the effect\ninactivationmethodsoninfluenzavirionstooptimize.Vaccin.Prod.Vaccin.3\n1630\u20131637(2019).\n89. Li,J.T.,Rank,M.A.,Squillace,D.L.&Kita,H.Ovalbumincontentofinfluenz\nvaccines.J.AllergyClin.Immunol.125,1412\u20131413(2010).authorreply1413-141\n90. Garcia-Canas, V. et al. Selective and quantitative detection of influenza viru\nproteinsincommercialvaccinesusingtwo-dimensionalhigh-performanceliqui\nchromatographyandfluorescencedetection.Anal.Chem.79,3164\u20133172(2007\n91. Garcia-Canas,V.,Lorbetskie,B.&Girard,M.Rapidandselectivecharacterization\ninfluenzavirusconstituentsinmonovalentandmultivalentpreparationsusin\nnon-porousreversed-phasehighperformanceliquidchromatographycolumns.\nChromatogr.A1123,225\u2013232(2006)."
    },
    {
      "element_id": "elem_008_0076",
      "page_num": 8,
      "element_type": "title",
      "bbox": [
        311.48962646484375,
        536.7035302734375,
        374.589580078125,
        546.1002685546874
      ],
      "confidence": 0.5391474366188049,
      "reading_order": 3,
      "content": "TheAuthor(s)202"
    },
    {
      "element_id": "elem_008_0077",
      "page_num": 8,
      "element_type": "title",
      "bbox": [
        310.2955224609375,
        310.4438818359375,
        426.0488818359375,
        321.2746435546875
      ],
      "confidence": 0.9886133670806885,
      "reading_order": 4,
      "content": "ADDITIONAL INFORMATION"
    },
    {
      "element_id": "elem_008_0078",
      "page_num": 8,
      "element_type": "title",
      "bbox": [
        310.2853051757812,
        261.522861328125,
        407.6010791015625,
        272.5695703125
      ],
      "confidence": 0.9792298674583435,
      "reading_order": 5,
      "content": "COMPETINGINTERESTS"
    },
    {
      "element_id": "elem_008_0079",
      "page_num": 8,
      "element_type": "title",
      "bbox": [
        310.1530517578125,
        195.25493408203124,
        416.3020751953125,
        206.31254150390623
      ],
      "confidence": 0.9977368116378784,
      "reading_order": 6,
      "content": "AUTHORCONTRIBUTIONS"
    },
    {
      "element_id": "elem_008_0080",
      "page_num": 8,
      "element_type": "title",
      "bbox": [
        311.18690917968746,
        121.07965209960938,
        403.5185595703125,
        131.647939453125
      ],
      "confidence": 0.993751585483551,
      "reading_order": 7,
      "content": "ACKNOWLEDGEMENTS"
    },
    {
      "element_id": "elem_008_0081",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        312.8496459960937,
        425.94319335937496,
        559.4053271484374,
        515.6194921875
      ],
      "confidence": 0.9889256358146667,
      "reading_order": 8,
      "content": "Attribution 4.0 International License, which permits use, sharing,\ndaptation,distributionandreproductioninanymediumorformat,aslongasyougive\nppropriatecredittotheoriginalauthor(s)andthesource,providealinktotheCreative\nommonslicense,andindicateifchangesweremade.Theimagesorotherthirdparty\naterialinthisarticleareincludedinthearticle\u2019sCreativeCommonslicense,unless\nndicatedotherwiseinacreditlinetothematerial.Ifmaterialisnotincludedinthe\nrticle\u2019sCreativeCommonslicenseandyourintendeduseisnotpermittedbystatutor\negulationorexceedsthepermitteduse,youwillneedtoobtainpermissiondirectly\nromthecopyrightholder.Toviewacopyofthislicense,visithttp://creativecommons."
    },
    {
      "element_id": "elem_008_0082",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        311.91277587890625,
        377.5162060546875,
        560.95435546875,
        393.761689453125
      ],
      "confidence": 0.9508141279220581,
      "reading_order": 9,
      "content": "ublishersnoteSpringerNatureremainsneutralwithregardtojurisdictionalclaims\nnpublishedmapsandinstitutionalaffiliations."
    },
    {
      "element_id": "elem_008_0083",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        310.23169189453125,
        350.74430419921873,
        559.8204345703125,
        368.11878662109376
      ],
      "confidence": 0.7079799771308899,
      "reading_order": 10,
      "content": "reprints"
    },
    {
      "element_id": "elem_008_0084",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        310.285634765625,
        350.49781494140626,
        559.1132666015625,
        359.39256591796874
      ],
      "confidence": 0.5321225523948669,
      "reading_order": 11,
      "content": "Reprints and permission information is available at http://www.nature.com"
    },
    {
      "element_id": "elem_008_0085",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        309.8444677734375,
        323.2904150390625,
        563.9789355468749,
        341.01635009765624
      ],
      "confidence": 0.9698144793510437,
      "reading_order": 12,
      "content": "Correspondence and requests for materials should be addressed to Arun B.\nArunachalam."
    },
    {
      "element_id": "elem_008_0086",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        311.0895263671875,
        274.89796875,
        557.7861181640625,
        292.10737060546876
      ],
      "confidence": 0.9914585947990417,
      "reading_order": 13,
      "content": "All authors are employees of Sano Pasteur and may hold shares and/or stoc\noptionsinthecompany."
    },
    {
      "element_id": "elem_008_0087",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        311.89025390625,
        209.026669921875,
        558.2255712890625,
        244.46414794921873
      ],
      "confidence": 0.9942757487297058,
      "reading_order": 14,
      "content": ".A.conceptualised,designed,andpreparedtheoriginaldraftandFig.2;D.R.andP.\nxpandedtheclinicalandtheregulatorysectionsrespectively;allauthorsreviewe\nndcommentedonthemanuscriptatallstages,approvedthefinaldraft,andremai\nccountablefortheaccuracyandintegrityofthework."
    },
    {
      "element_id": "elem_008_0088",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        312.4850537109375,
        134.10763549804688,
        558.5466796874999,
        177.60253051757812
      ],
      "confidence": 0.9962131977081299,
      "reading_order": 15,
      "content": "ditorialassistancewiththepreparationofthemanuscriptwasprovidedbyJuliett\nray,inScienceCommunications,SpringerHealthcareLtd,UKandwasfundedb\nanofi Pasteur. Graphic design support provided by Naveen Kandibanda (Sanofi)\nheauthorsalsothankKathrynBonaparte(SanofiPasteur)foreditorialassistancean\nanuscriptcoordination."
    },
    {
      "element_id": "elem_008_0089",
      "page_num": 8,
      "element_type": "list",
      "bbox": [
        309.44729003906247,
        59.36978759765625,
        560.5887744140625,
        104.46802734375
      ],
      "confidence": 0.737604558467865,
      "reading_order": 16,
      "content": "92. Lin,Y.T.etal.Correlationofovalbuminofeggwhitecomponentswithallergic\ndiseasesinchildren.J.Microbiol.Immunol.Infect.49,112\u2013118(2016).\n93. Vaccineexcipientsummary.Availableathttps://www.cdc.gov/vaccines/pubs/\npinkbook/downloads/appendices/b/excipient-table-2.pdf. Accessed August\n2021."
    },
    {
      "element_id": "elem_008_0090",
      "page_num": 8,
      "element_type": "text",
      "bbox": [
        308.3991064453125,
        58.297961425781246,
        562.49208984375,
        104.4760693359375
      ],
      "confidence": 0.535094141960144,
      "reading_order": 17,
      "content": "92. Lin,Y.T.etal.Correlationofovalbuminofeggwhitecomponentswithallergic\ndiseasesinchildren.J.Microbiol.Immunol.Infect.49,112\u2013118(2016).\n93. Vaccineexcipientsummary.Availableathttps://www.cdc.gov/vaccines/pubs/\npinkbook/downloads/appendices/b/excipient-table-2.pdf. Accessed August\n2021."
    }
  ],
  "statistics": {
    "total_elements": 90,
    "text_extracted": 88,
    "image_references": 2,
    "by_type": {
      "title": 19,
      "text": 60,
      "list": 9,
      "figure": 2
    },
    "by_page": {
      "1": 16,
      "2": 10,
      "3": 9,
      "4": 5,
      "5": 11,
      "6": 17,
      "7": 5,
      "8": 17
    }
  }
}